{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:43:10Z","timestamp":1793032990788,"version":"4.5.0"},"reference-count":33,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2024,5,31]]},"DOI":"10.1536\/ihj.23-485","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T22:14:43Z","timestamp":1717107283000},"page":"528-536","source":"Crossref","is-referenced-by-count":5,"title":["MiR-378 Inhibits Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting AKT2"],"prefix":"10.1536","volume":"65","author":[{"given":"Guili","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Beijing Xiaotangshan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Beijing Xiaotangshan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Beijing Xiaotangshan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqiang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Beijing Xiaotangshan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Beijing Xiaotangshan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kairouz V, Lipskaia L, Hajjar RJ, Chemaly ER. Molecular targets in heart failure gene therapy: current controversies and translational perspectives. Ann N Y Acad Sci 2012; 1254: 42-50.","DOI":"10.1111\/j.1749-6632.2012.06520.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016; 97: 245-62.","DOI":"10.1016\/j.yjmcc.2016.06.001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mukku RB, Fonarow GC, Watson KE, <i>et al<\/i>. Heart failure therapies for end-stage chemotherapy-induced cardiomyopathy. J Card Fail 2016; 22: 439-48.","DOI":"10.1016\/j.cardfail.2016.04.009"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.","DOI":"10.1146\/annurev.physiol.65.092101.142243"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. McMullen JR, Sherwood MC, Tarnavski O, <i>et al<\/i>. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050-5.","DOI":"10.1161\/01.CIR.0000130641.08705.45"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sen S, Kundu BK, Wu HCJ, <i>et al<\/i>. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc 2013; 2: e004796.","DOI":"10.1161\/JAHA.113.004796"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gao W, Guo N, Zhao S, <i>et al<\/i>. Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling. Biosci Rep 2020; 40: 20200669.","DOI":"10.1042\/BSR20200669"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011; 13: e11.","DOI":"10.1017\/S1462399411001815"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. He F, Liu H, Guo J, <i>et al<\/i>. Inhibition of MicroRNA-124 reduces cardiomyocyte apoptosis following myocardial infarction via targeting STAT3. Cell Physiol Biochem 2018; 51: 186-200.","DOI":"10.1159\/000495173"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yuan J, Chen H, Ge D, <i>et al<\/i>. miR-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7. Cell Physiol Biochem 2017; 42: 2207-19.","DOI":"10.1159\/000479995"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Xiao Y, Zhang X, Fan S, Cui G, Shen Z. MicroRNA-497 inhibits cardiac hypertrophy by targeting Sirt4. PLOS ONE 2016; 11: e0168078.","DOI":"10.1371\/journal.pone.0168078"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Orenes-Pi\u00f1ero E, Montoro-Garc\u00eda S, Patel JV, Vald\u00e9s M, Mar\u00edn F, Lip GY. Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol 2013; 167: 1651-9.","DOI":"10.1016\/j.ijcard.2012.09.120"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Huang S, Zou X, Zhu JN, <i>et al<\/i>. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy. J Cell Mol Med 2015; 19: 608-19.","DOI":"10.1111\/jcmm.12445"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pan W, Zhong Y, Cheng C, <i>et al<\/i>. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLOS ONE 2013; 8: e53950.","DOI":"10.1371\/journal.pone.0053950"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Song L, Su M, Wang S, <i>et al<\/i>. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med 2014; 18: 2266-74.","DOI":"10.1111\/jcmm.12380"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li C, Li X, Gao X, <i>et al<\/i>. MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol 2014; 173: 268-76.","DOI":"10.1016\/j.ijcard.2014.02.035"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sharma S, Liu J, Wei J, Yuan H, Zhang T, Bishopric NH. Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO Mol Med 2012; 4: 617-32.","DOI":"10.1002\/emmm.201200234"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol 2016; 68: 2577-84.","DOI":"10.1016\/j.jacc.2016.09.945"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yuan J, Liu H, Gao W, <i>et al<\/i>. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress. Theranostics 2018; 8: 2565-82.","DOI":"10.7150\/thno.22878"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Barut Z, Cabbar AT, Yilmaz SG, <i>et al<\/i>. Investigation of circulating miRNA-133, miRNA-26, and miRNA-378 as candidate biomarkers for left ventricular hypertrophy. In Vivo 2021; 35: 1605-10.","DOI":"10.21873\/invivo.12417"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Matkovich SJ, Van Booven DJ, Youker KA, <i>et al<\/i>. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009; 119: 1263-71.","DOI":"10.1161\/CIRCULATIONAHA.108.813576"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Ganesan J, Ramanujam D, Sassi Y, <i>et al<\/i>. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013; 127: 2097-106.","DOI":"10.1161\/CIRCULATIONAHA.112.000882"},{"key":"24","first-page":"220","volume":"2","year":"2003","unstructured":"24. Matsui T, Nagoshi T, Rosenzweig A.A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2003; 2: 220-3.","journal-title":"Cell Cycle","ISSN":"https:\/\/id.crossref.org\/issn\/1538-4101","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gong Y, Li G, Tao J, <i>et al<\/i>. Double knockout of Akt2 and AMPK accentuates high fat diet-induced cardiac anomalies through a cGAS-STING-mediated mechanism. Biochim Biophys Acta Mol Basis Dis 2020; 1866: 165855.","DOI":"10.1016\/j.bbadis.2020.165855"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Chen D, Chen F, Xu Y, <i>et al<\/i>. AKT2 deficiency induces retardation of myocyte development through EndoG-MEF2A signaling in mouse heart. Biochem Biophys Res Commun 2017; 493: 1410-7.","DOI":"10.1016\/j.bbrc.2017.09.149"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Okwuosa TM, Soliman EZ, Lopez F, Williams KA, Alonso A, Ferdinand KC. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J 2015; 169: 155-61.","DOI":"10.1016\/j.ahj.2014.09.013"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-9.","DOI":"10.1126\/science.1139089"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Qiang Z, Jin B, Peng Y, <i>et al<\/i>. miR-762 modulates thyroxine-induced cardiomyocyte hypertrophy by inhibiting Beclin-1. Endocrine 2019; 66: 585-95.","DOI":"10.1007\/s12020-019-02048-y"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Song G, Zhu L, Ruan Z, Wang R, Shen Y. MicroRNA-122 promotes cardiomyocyte hypertrophy via targeting FoxO3. Biochem Biophys Res Commun 2019; 519: 682-8.","DOI":"10.1016\/j.bbrc.2019.09.035"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Reinartz M, Raupach A, Kaisers W, G\u00f6decke A. AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 2014; 13: 4232-45.","DOI":"10.1021\/pr500131g"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Debosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem 2006; 281: 32841-51.","DOI":"10.1074\/jbc.M513087200"},{"key":"33","unstructured":"33. Etzion S, Etzion Y, DeBosch B, <i>et al<\/i>. Akt2 deficiency promotes cardiac induction of Rab4a and myocardial \u03b2-adrenergic hypersensitivity. Biochem Biophys Res Commun 2017; 493: 1410-7."}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/3\/65_23-485\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T04:16:13Z","timestamp":1717215373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/3\/65_23-485\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-485","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"article-number":"23-485"}}